Please click here to access the ELIQUIS Patient Information Leaflet.
*In the ARISTOTLE trial, a total of 18,201 patients with NVAF and one risk factor for stroke and mean CHADS2 score of 2.1 were randomised to ELIQUIS 5mg BD (or 2.5 mg BD in selected patients [4.7%]) or warfarin adjusted to target INR range range 2.0–3.0. Stroke or systemic embolism was the primary efficacy endpoint of the ARISTOTLE trial (hameorrhagic stroke and ischaemic or undetermined stroke were components of stroke) and major bleeding defined per International Society on Thrombosis and Heamostasis (ISTH) criteria were the primary endpoint. Efficacy analyses based on the intention-to-treat population. Safety analyses based on patients who had at least one dose of study drug.2
BD = Twice Daily CHADS2 = Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke (doubled) CrCl = Creatine Clearance INR = International Normalised Ratio NVAF = Non-Valvular Atrial Fibrillation
ELIQUIS® (apixaban) Summary of Product Characteristics.
Granger CB et al. N Engl J Med 2011; 365: 981–992.
You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.
All corporate names and logos of BMS and/or of its products are trademarks of Bristol-Myers Squibb Company and are protected by national and international intellectual and industrial property laws. All rights reserved over the content of this website.